Verve Therapeutics Alpha and Beta Analysis
| VERVDelisted Stock | USD 11.13 0.00 0.00% |
This module allows you to check different measures of market premium (i.e., alpha and beta) for all equities such as Verve Therapeutics. It also helps investors analyze the systematic and unsystematic risks associated with investing in Verve Therapeutics over a specified time horizon. Remember, high Verve Therapeutics' alpha is almost always a sign of good performance; however, a high beta will depend on investors' risk tolerance level and may signal increased volatility and potential future overvaluation. Key technical indicators related to Verve Therapeutics' market risk premium analysis include:
Beta (0.74) | Alpha 1.61 | Risk 0.0 | Sharpe Ratio 0.0 | Expected Return 0.0 |
Alpha is a measure of relative performance on a risk-adjusted basis, while beta measures volatility against the benchmark. The goal is to know if an investor is being compensated for the volatility risk taken. The return on investment might be better than its reference but still not compensate for the assumption of the risk.
Verve |
Verve Therapeutics Market Premiums
Investors always prefer to have the highest possible return on investment, coupled with the lowest possible volatility. Verve Therapeutics market risk premium is the additional return an investor will receive from holding Verve Therapeutics long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in Verve Therapeutics. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Alpha and beta are two of the key measurements used to evaluate Verve Therapeutics' performance over market.| α | 1.61 | β | -0.74 |
Verve Therapeutics Fundamentals Vs Peers
Comparing Verve Therapeutics' fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze Verve Therapeutics' direct or indirect competition across all of the common fundamentals between Verve Therapeutics and the related equities. This way, we can detect undervalued stocks with similar characteristics as Verve Therapeutics or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of Verve Therapeutics' fundamental indicators could also be used in its relative valuation, which is a method of valuing Verve Therapeutics by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare Verve Therapeutics to competition |
| Fundamentals | Verve Therapeutics | Peer Average |
| Return On Equity | -0.34 | -0.31 |
| Return On Asset | -0.19 | -0.14 |
| Operating Margin | (1.11) % | (5.51) % |
| Current Valuation | 565.6 M | 16.62 B |
| Shares Outstanding | 89.31 M | 571.82 M |
| Shares Owned By Insiders | 5.10 % | 10.09 % |
| Shares Owned By Institutions | 94.68 % | 39.21 % |
Verve Therapeutics Opportunities
Verve Therapeutics Return and Market Media
The Stock received substential amount of media coverage during this period. Price Growth (%) |
| Timeline |
1 | Verve Therapeutics Q1 Earnings Snapshot | 05/14/2025 |
2 | Verve Therapeutics Just Reclaimed the 200-Day Moving Average | 06/06/2025 |
3 | Verve Therapeutics Inc Under Investigation for Proposed Sale to Eli Lilly VERV stock news | 06/17/2025 |
4 | Why Lillys Bid for Verve Therapeutics Sent the Stock Soaring This Week | 06/20/2025 |
5 | Lilly To Acquire Verve For One-Time Cardiovascular Treatments | 06/23/2025 |
6 | Verve Therapeutics Stock Price, News Analysis - MarketBeat | 07/03/2025 |
7 | Goldman Spotlights These 3 Stocks in Its Bullish SP 500 Outlook | 07/15/2025 |
8 | Verve Therapeutics Stock Soars as Eli Lilly Buys Gene-Editing Firm for 1.3B - MSN | 07/22/2025 |
9 | Lilly completes acquisition of Verve Therapeutics to advance one-time treatments for people with high cardiovascular risk | 07/25/2025 |
About Verve Therapeutics Beta and Alpha
For many years both, Alpha and Beta indicators are used by professional money managers as critical performance measurement tools across virtually all financial instruments including Verve or other delisted stocks. Alpha measures the amount that position in Verve Therapeutics has returned in comparison to a selected market index or another relevant benchmark. In other words, Alpha is the excess return on an investment relative to the performance of your selected benchmark. Beta, on the other hand, measures the relative risk of your investment.
Verve Therapeutics Upcoming Company Events
As portrayed in its financial statements, the presentation of Verve Therapeutics' financial position is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Verve Therapeutics' leadership is honest, while the outside auditors are strict and uncompromising. Whatever the case, investors should always follow all of Verve Therapeutics' public filing events to personally review all filings and be reasonable and skeptical to interpret all of the financial statements of Verve Therapeutics. Please utilize our Beneish M Score to check the likelihood of Verve Therapeutics' management manipulating its earnings.
| 7th of March 2024 Upcoming Quarterly Report | View | |
| 20th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 7th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Build Portfolio with Verve Therapeutics
Your optimized portfolios are the building block of your wealth. We provide an intuitive interface to determine which securities in a portfolio should be removed or rebalanced to achieve better diversification, find the right mix of securities that minimizes portfolio risk for a given return, or maximize portfolio expected return for a given risk level.Build Diversified Portfolios
Align your risk with return expectations
Check out World Market Map to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population. You can also try the Headlines Timeline module to stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity.
Other Consideration for investing in Verve Stock
If you are still planning to invest in Verve Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Verve Therapeutics' history and understand the potential risks before investing.
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| Share Portfolio Track or share privately all of your investments from the convenience of any device | |
| Commodity Directory Find actively traded commodities issued by global exchanges | |
| Global Correlations Find global opportunities by holding instruments from different markets | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio |